Russia is expected to approve its second vaccine on October 15. The second coronavirus vaccine has been developed by Siberia’s Vector Institute, which completed early-stage human trials of the vaccine last month.
Russia has already registered its first coronavirus vaccine with the name Sputnik V.
Vaccine developer’s said on Friday that Russia is all set to register its second coronavirus vaccine on 15 October.
According to reports, the experimental vaccine has recently completed its early stage of human trials and is developed by Vector State Research Center of Virology and Biotechnology.
“The Healthcare Ministry of the Russian Federation began the procedure of registration of the EpiVacCorona vaccine. The completion of the registration procedure of the EpiVacCorona vaccine is planned by October 15, 2020,” the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing earlier reported.
According to TASS report, the Vector Research Center obtained the Russian Health Ministry’s permission to conduct clinical trials of its vaccine on volunteers in July. On July 27 the first volunteer was injected with the vaccine and on September 8, the final groups of 20 volunteers were discharged from the medical facility.
Russia’s chief sanitary doctor Anna Popova said, “The clinical trials have been very successful. The volunteers are developing the necessary titers and no one has any clinical signs after the vaccine – neither temperature nor any other reaction.”
ALSO READ |Sputnik v 60000 sign up for vaccine trials
The Phase III trials will be started by the drug manufactures in November-December. About 30,000 volunteers will be taking part in post-registration trials of the coronavirus vaccine, according to reports. And on the industrial site of the Vector research center the vaccine will be manufactured.
According to TASS, the sanitary watchdog’s press service explained, “After the registration of the EpiVacCorona vaccine in October 2020 clinical trials are planned with the participation of volunteers of the age group of over 60 and those with chronic illnesses, as well as placebo-controlled post-registration clinical trials involving 5,000 adult volunteers of different age groups.”
“There are not many such vaccines in the world, which are being developed by the Vector Center. This is a rather complicated process,” said Popova
ALSO READ| India to get a supply of 100 million doses of sputnik-v vaccine from Russia after regulatory approvals
A month back, even before the final trial Russia had approved a COVID-19 vaccine named Sputnik V. Currently it is undergoing its final trials in Russia on around 40,000 subjects.
Gamaleya National Research Center of Epidemiology and Microbiology and RDIF, has developed Sputnik V.
Dr. Reddy’s spoke to @SputnikInt about the RDIF (Russian Direct Investment Fund) and Dr. Reddy’s collaboration on clinical trials and distribution of the Sputnik V vaccine to India. Read the full interview here: https://t.co/wljVcJZyRf
— Dr. Reddy’s (@drreddys) September 22, 2020
Indian pharma company Dr Reddy’s has collaborated with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V vaccine as well as for its distribution.